Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM20Q5O)

• Drug Name: SB-747651A Drug Info
• Synonyms: SB-747651A; CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11393719
  TTD Drug ID: DM20Q5O

Molecule-Related Drug Atlas

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[4]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[5]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[6]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[7]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[8]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[9]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[9]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[9]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[9]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[9]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[10]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[10]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[10]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[11]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[12]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[13]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[14]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[15]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[10]
Triciribine prodrug	DMBN1XS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[14]

Drug(s) Targeting AKT3 messenger RNA (AKT3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 29202	DMDR8V9	Discovery agent	N.A.	Investigative	[16]
ISIS 29136	DMAMTLR	Discovery agent	N.A.	Investigative	[16]
ISIS 29112	DMECMA6	Discovery agent	N.A.	Investigative	[16]
ISIS 29161	DMPS6OQ	Discovery agent	N.A.	Investigative	[16]
ISIS 29200	DMN1LHI	Discovery agent	N.A.	Investigative	[16]
ISIS 29135	DMGJURC	Discovery agent	N.A.	Investigative	[16]
ISIS 29177	DMSUWVE	Discovery agent	N.A.	Investigative	[16]
ISIS 29160	DM9NB1A	Discovery agent	N.A.	Investigative	[16]
ISIS 29176	DMVLU5J	Discovery agent	N.A.	Investigative	[16]
ISIS 29159	DMLE1IJ	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting Ribosomal protein S6 kinase beta-1 (S6K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
NNI-362	DMPCV65	Alzheimer disease	8A20	Phase 1	[17]
PF-4708671	DMO0892	Ulcerative colitis	DD71	Clinical trial	[18]
PMID27410995-Compound-Figure3c	DMDQMZT	N. A.	N. A.	Patented	[19]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	DM6O2Q9	N. A.	N. A.	Patented	[19]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[20]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[21]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[22]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[20]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AKT3 messenger RNA (AKT3 mRNA)	TTO6SGY	AKT3_HUMAN	Inhibitor	[2]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[2]
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[2]
Ribosomal protein S6 kinase beta-1 (S6K1)	TTG0U4H	KS6B1_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8130).
• [2] Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79.
• [3] (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3407-11.
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
• [6] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
• [9] Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [15] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [16] US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
• [17] Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
• [18] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [19] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
• [20] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [21] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [22] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.